Literature DB >> 29580759

Uveitis and serous retinal detachment secondary to systemic dabrafenib and trametinib.

T Rueda-Rueda1, J L Sánchez-Vicente1, A Moruno-Rodríguez2, F E Molina-Socola1, A C Martínez-Borrego1, F López-Herrero1.   

Abstract

CASE REPORT: The case is presented of a 39-year-old woman with metastatic melanoma treated with dabrafenib and trametinib. She presented with a severe acute panuveitis with granulomatous anterior uveitis, vitritis, and multiple serous retinal detachments. Dabrafenib and trametinib were suspended, and treatment with a systemic and topical corticosteroid was started. A good response was obtained, with a recovery of visual acuity of 1.0 in both eyes within two weeks. DISCUSSION: Dabrafenib and trametinib can lead to severe uveitis. Treatment with corticosteroids and discontinuation of therapy with dabrafenib and trametinib led to an anatomical and functional improvement, and resolved the episode rapidly. Ophthalmologists must be aware of this toxicity, given the increasing use of those drugs.
Copyright © 2018 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Dabrafenib; Desprendimiento seroso de retina; Inhibidores MAPK; MAPK inhibitors; Melanoma; Panuveitis; Panuveítis; Serous retinal detachment; Trametinib

Mesh:

Substances:

Year:  2018        PMID: 29580759     DOI: 10.1016/j.oftal.2018.01.008

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol (Engl Ed)        ISSN: 2173-5794


  2 in total

1.  Mediastinal and hilar sarcoid-like reaction in a patient treated with dabrafenib and trametinib for metastatic melanoma: A case report and review of the literature.

Authors:  Vanessa-Meletia Bala; Maria Mitsogianni; Konstantinos Laschos; Evangelia Pliakou; Eirini Lazaridi; Dimitra-Ioanna Lampropoulou; Gerasimos Aravantinos
Journal:  Mol Clin Oncol       Date:  2022-03-18

2.  Retinal Vein Occlusion in a Patient on Dabrafenib and Trametinib Therapy for Metastatic Melanoma.

Authors:  Mercedes Molero-Senosiain; Maria Liseth Salazar; Irene Camacho; Blanca Benito-Pascual; Clara Valor-Suarez
Journal:  Cureus       Date:  2022-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.